Can higher hemoglobin increase blood viscosity and raise thrombotic risk?

The relationship between hemoglobin levels, blood rheology, and cardiovascular risk is a critical consideration in clinical medicine. As a primary determinant of hematocrit, hemoglobin directly influences the physical properties of blood, with significant implications for flow dynamics and clotting risk.

Hemoglobin and Whole-Blood Viscosity

Hemoglobin concentration is the dominant driver of whole-blood viscosity (WBV). This relationship is non-linear; as hemoglobin rises, viscosity increases at an accelerating rate.

• Rheological Impact: Increased hemoglobin expands the red blood cell (RBC) volume fraction (hematocrit). Higher RBC concentrations facilitate the formation of aggregates (rouleaux), which exponentially raises flow resistance, particularly in low-shear environments like the venous system.
• Cellular Biomechanics: Elevated intracellular hemoglobin (measured as MCHC) reduces the deformability of individual RBCs. Less flexible cells cannot easily deform to pass through narrow vessels, further increasing the overall viscosity of the blood.

Microvascular Flow Dynamics

The microvasculature is particularly sensitive to changes in blood viscosity. According to Poiseuille’s Law, resistance to flow is directly proportional to the viscosity of the fluid.

• Perfusion Resistance: Clinical and experimental models show that when hemoglobin reaches high-normal or elevated levels (e.g., ≥21 g/dL in high-altitude erythrocytosis), viscosity can increase by nearly 50%, leading to a direct reduction in microcirculatory velocity.
• "Sludging" Effect: In the narrowest capillaries (5–10 μm), high RBC concentrations can lead to microvascular "sludging." This phenomenon impairs oxygen delivery and can induce endothelial dysfunction due to the increased shear stress required to move the viscous blood.

Thrombotic Risk and Clinical Outcomes

Elevated hemoglobin is a documented risk factor for both venous and arterial thrombosis.

• Venous Thromboembolism (VTE): Large-scale cohort studies, including the British Regional Heart Study, demonstrate a significant positive association between hemoglobin levels and VTE risk. Mendelian randomization using UK Biobank data suggests this relationship is likely causal.
• Cardiovascular Events: High-normal hemoglobin levels (e.g., >150 g/L) have been linked to a 39% increase in cardiovascular mortality and a higher risk of major adverse cardiovascular events (MACE) in patients following myocardial infarction.
• Clinical Populations: In patients with erythrocytosis, the risk of rare thrombotic events can be up to four times higher than in those with normal hemoglobin levels, primarily driven by the hyperviscosity-mediated prothrombotic state.

Bottom line

Higher hemoglobin levels significantly increase whole-blood viscosity by increasing red blood cell volume and reducing cell deformability. This leads to increased flow resistance and reduced velocity in the microvasculature, ultimately contributing to a higher risk of both venous and arterial thrombosis.